|LAKELAND, Fla., and SEATTLE -- Lakeland Regional Cancer Center and Rosetta Biosoftware announced today that Lakeland Regional Cancer Center licensed the Rosetta Resolver(R) system to investigate the clinical value of microarrays for assisting in cancer staging, the process of describing the severity of a cancer at the time of diagnosis.
"The Resolver system is a comprehensive and scalable informatics solution that addresses the gene expression data analysis and management needs for biomarker discovery in cancer research," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "We are pleased to provide Lakeland Regional Cancer Center with tools to advance research in facilitating prognosis on a molecular level."
"In our Molecular Staging Laboratory, we test the clinical value of various molecular assays for cancer staging," said Steven C. Shivers, Ph.D., associate director for basic science and translational research and director of the Molecular Staging Laboratory at Lakeland Regional Cancer Center. "The Resolver system will be an important tool for investigating the clinical value of oligonucleotide microarrays. The reliability and flexibility of the Resolver system will benefit various cancer staging applications, including the discovery of prognostic and/or therapy-responsive biomarkers."
The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.